ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Zenas BioPharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$26.71+1.87 (+7.53%)
Close on Oct 19, 2026
- Market cap
- $1.69B
- P/E (TTM)
- –
- Dividend yield
- –
Zenas BioPharma, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -4755.7%
- Net margin
- -4843.8%
- Return on equity, FY2025
- -136.2%
Financial strength
- Current ratio
- 9.93
- Debt to equity
- 0.90
- Debt to assets
- 31.8%
- Cash to current liabilities
- 298.7%
Valuation
- P/E ratio
- –
- Price to sales
- 168.57
- Price to book
- 6.82
- Dividend yield
- –